Department of Pediatrics, Neonatal-Perinatal Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
University of Oklahoma College of Medicine, Oklahoma City, Oklahoma.
Am J Perinatol. 2024 May;41(S 01):e1069-e1074. doi: 10.1055/a-1990-8311. Epub 2022 Nov 30.
The U.S. opioid epidemic has been characterized by increases in opioid misuse, overdose deaths, and neonatal opioid withdrawal syndrome. Research suggests that marijuana legalization has contributed to decreased use of opiates, although many studies had methodological weaknesses and failed to address the pregnant population. Implementation of medical cannabis laws has the potential to reduce maternal opioid use and, therefore, neonatal exposure to the drugs. This study aimed to examine the association between Oklahoma's implementation of state medical marijuana laws and the neonatal exposure to opioids.
Electronic medical records at two sites (Oklahoma City and Lawton) were searched for results of cord, urine, and meconium screens to detect amphetamines, barbiturates, benzodiazepines, cocaine, ethanol, opiates, phencyclidine, and tetrahydrocannabinol (THC). Two study periods were compared: 19 months before Oklahoma's medical marijuana law took effect and 19 months after legalization began.
A total of 16,804 babies were born alive at the two sites during the study period. The rate of positive THC tests per 1,000 liveborn infants significantly increased from 16.2 per 1,000 during the prelaw period to 22.2 per 1,000 during the postlaw period ( = 0.004). Neonatal opioid exposure incidence showed a nonsignificant decrease from 7.6 positive tests per 1,000 liveborn infants to 6.8 per 1,000 from prelaw to postlaw period ( = 0.542). The number of positive tests for THC and concomitant use of opioids doubled from the prelaw period ( = 4) to postlaw ( = 9), but there were too few cases for statistical significance. Infants at the more rural site had significantly higher rates for amphetamines, benzodiazepines, and THC, with a trend toward higher rates for opiates.
Marijuana legalization was related to significant increases in positive test rates for THC, but no significant change/association was noted for neonatal exposure to opioids.
· Prior studies have not examined neonatal exposure to opioids following marijuana legalization.. · Oklahoma's new law led to higher neonatal marijuana exposure.. · Legalization of medical marijuana did not change Oklahoma's neonatal opioid positivity rate..
美国阿片类药物滥用危机的特点是阿片类药物滥用、过量死亡和新生儿阿片类药物戒断综合征的增加。研究表明,大麻合法化导致阿片类药物使用减少,尽管许多研究存在方法学上的缺陷,并且没有解决孕妇人群的问题。实施医用大麻法有可能减少产妇阿片类药物的使用,从而减少新生儿接触这些药物。本研究旨在探讨俄克拉荷马州实施州医用大麻法与新生儿接触阿片类药物之间的关联。
在两个地点(俄克拉荷马城和劳顿)的电子病历中搜索了用于检测安非他命、巴比妥类药物、苯二氮卓类、可卡因、乙醇、阿片类药物、苯环利定和四氢大麻酚(THC)的脐血、尿液和胎粪检测结果。比较了两个研究期:俄克拉荷马州医用大麻法生效前的 19 个月和合法化开始后的 19 个月。
在研究期间,两个地点共有 16804 名活产婴儿出生。每 1000 名活产婴儿中阳性 THC 检测率从法律实施前的每 1000 名 16.2 例显著增加到法律实施后的每 1000 名 22.2 例(=0.004)。新生儿阿片类药物暴露发生率从每 1000 名活产婴儿中 7.6 例阳性检测呈下降趋势,但无统计学意义,从法律实施前的每 1000 名 6.8 例降至法律实施后的每 1000 名 6.8 例(=0.542)。THC 阳性检测和同时使用阿片类药物的数量从法律实施前的 4 例增加到法律实施后的 9 例,几乎增加了一倍,但由于病例数量太少,无法进行统计学意义上的分析。在较农村的地点,安非他命、苯二氮卓类和 THC 的阳性检测率显著较高,阿片类药物的阳性检测率也呈上升趋势。
大麻合法化与 THC 阳性检测率的显著增加有关,但新生儿阿片类药物暴露率没有显著变化/关联。
· 先前的研究没有检查大麻合法化后新生儿接触阿片类药物的情况。· 俄克拉荷马州的新法律导致新生儿接触大麻的比例上升。· 医用大麻合法化并未改变俄克拉荷马州新生儿阿片类药物阳性率。